This project will collect blood and liver tissue samples of unexplained and newly emerging acute hepatitis through a monitoring system. After excluding infections of hepatitis A-E viruses using enzyme immunoassay, chemical, and photometric methods to detect infection markers, multiplex PCR technology will be employed to screen for related pathogens. The goal is to establish a sensitive, rapid, and accurate diagnostic system.
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Exhibiting symptoms of acute hepatitis;
2. Medical history, signs, and auxiliary examinations suggest hepatitis, but the cause is unknown or it is non-hepatotropic viral hepatitis;
3. Newly discovered pathogen infection or hepatitis caused by factors other than currently known ones;
4. The subject voluntarily participates in this study and signs the informed consent form.
Exclusion Criteria:
1. Patients with a clear etiology and diagnosis of hepatitis;
2. Patients who refuse to cooperate with sampling and sign the informed consent form;
3. Those deemed unsuitable for participation in this study by the researchers.
Primary outcome measure(s)
Forms of outcomes — three years Validation of the Diagnostic Performance of the Monitoring Network and Early Warning System for Unexplained and Newly Emerging Acute Hepatitis
Trial sites (1)
Facility
City
Region
Status
Beijing Ditan Hospital, Capital Medical University
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.